advance potent neutralizing mAbs against SARS-CoV-2 as therapeutics. However, historical
efforts to advance antiviral monoclonal antibodies (mAbs) for the treatment of other
respiratory infections have been met with categorical failures in the clinic. By investigating
the mechanism by which SARS-CoV-2 and similar viruses spread within the lung, along with
available biodistribution data for systemically injected mAb, we highlight the challenges …